Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis

Psychiatric Services

Volumn 47, Issue 1, 1996, Pages 52-56

  Honigfeld, Gilbert ^a,b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Sandoz Pharma Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

ADULT; AGRANULOCYTOSIS; ARTICLE; CAUSE OF DEATH; CLINICAL FEATURE; DATA ANALYSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; HUMAN; INCIDENCE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MORTALITY; SCHIZOPHRENIA;

EID: 0030046794     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/ps.47.1.52     Document Type: Article

References (5)

1. Health care reform for Americans with severe mental illnesses, report of the National Advisory Mental Health Council. American Journal of Psychiatry 150:1447-1465, 1993
2. Kane JM Honigfeld G, Singer J, et al: Clozapine for the treatment-resistant schizophrenic. Archives of General Psychiatry 45.789-796, 1988
3. Pisciotta AV: Agranulocytosis induced by certain phenothiazine derivatives. JAMA 208:1862-1868, 1969
4. Adams PC Mianierin-induced agranulocytosis. British Medical Journal 285:208-209, 1982
5. Coulter DM, Edwards IR: Mianserin and agranulocytosis in New Zealand. Lancet 336.785-787, 1990